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Abstract
Objectives Evaluate known breast cancer risk factors
in relation to breast density.
Methods We examined factors in relation to breast
density in 144,018 New Hampshire (NH) women with at
least one mammogram recorded in a statewide mam-
mography registry. Mammographic breast density was
measured by radiologists using the BI-RADS classifi-
cation; risk factors of interest were obtained from
patient intake forms and questionnaires.
Results Initial analyses showed a strong inverse
influence of age and body mass index (BMI) on breast
density. In addition, women with late age at menar-
che, late age at first birth, premenopausal women, and
those currently using hormone therapy (HT) tended
to have higher breast density, while those with greater
parity tended to have less dense breasts. Analyses
stratified on age and BMI suggested interactions,
which were formally assessed in a multivariable
model. The impact of current HT use, relative to
nonuse, differed across age groups, with an inverse
association in younger women, and a positive associ-
ation in older women (p < 0.0001 for the interaction).
The positive effects of age at menarche and age at
first birth, and the inverse influence of parity were less
apparent in women with low BMI than in those with
high BMI (p = 0.04, p < 0.0001 and p = 0.01, respec-
tively, for the interactions). We also noted stronger
positive effects for age at first birth in postmenopausal
women (p = 0.004 for the interaction). The multivar-
iable model indicated a slight positive influence of
family history of breast cancer.
Conclusions The influence of age at menarche and
reproductive factors on breast density is less evident
in women with high BMI. Density is reduced in young
women using HT, but increased in HT users of age 50
or more.
Keywords Hormone replacement therapy Æ
Reproductive history Æ Mammographic breast density
Introduction
Numerous studies have shown that breast density, as
assessed through mammography, is an important
breast cancer risk factor [1–5]. Relative to the lowest
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classification of breast density (fatty tissue), women
with the highest classification (extreme density) may
have a 2- to 6-fold increased risk of breast cancer [5–8].
In addition to its role in breast cancer risk, breast
density reduces mammographic accuracy [9–12],
potentially increasing the risk of a later stage breast
cancer diagnosis.
Previous studies indicate that established breast
cancer risk factors, including family history of breast
cancer, age at first birth, parity, and postmenopausal
hormone use, have similar associations with breast
density. In contrast, the influence of age at menarche,
which in most studies is inversely related to breast
cancer risk [e.g., 13–15], remains uncertain. Some
studies have found positive associations [6, 16, 17], at
least one suggests an inverse association [18], and
others found no relation between age at menarche on
breast density [19, 20].
In an effort to clarify inconsistent results from pre-
vious studies, we evaluated established breast cancer
risk factors in relation to breast density in a large
population of women enrolled in a statewide mam-
mography registry. Our intention was to determine
whether characteristics associated with breast cancer
risk were also related to breast density, a finding that
would be consistent with the notion that density
mediates breast cancer risk. We were particularly
interested in assessing the influence of menarcheal age.
Methods
The New Hampshire Mammography Network
(NHMN) registers all consenting women who undergo
mammography at participating mammographic facili-
ties in our state. Details of the registry have been de-
scribed previously [21, 22]. For the present study,
potentially eligible women were NH residents of ages
30–89, who had at least one mammogram registered in
the NHMN from 1 May 1996 to 20 June 2002.
The epidemiological data used in this analysis arose
from three sources: a self-administered questionnaire
completed by the patient, a patient intake form
administered face-to-face by the radiologic technolo-
gist, and a standardized clinical assessment form com-
pleted by the radiologist. The questionnaire collected
height, weight, place of birth, ethnicity, marital status,
education, insurance coverage, reason for the current
visit, past history of clinical breast examinations and
mammography, age at menarche, parity, and age at
first birth. The questionnaire also queried women
regarding the date of their last menstrual period and
history of gynecological surgery. This information was
used to classify women as premenopausal (still having
periods naturally) or postmenopausal (periods had
stopped permanently) either naturally, because of
chemotherapy/radiation, or surgery). The patient in-
take form obtained date of birth, family history of
breast cancer (in the subject’s mother, sister, daughter,
or other relative), personal history of breast cancer,
history of breast procedures, type of exam conducted
at current visit, examination outcomes, recommenda-
tion for further work-up or follow-up, and current use
of postmenopausal hormone therapy (HT). The clini-
cal assessment form obtained the type of exam con-
ducted at current visit, breast density, examination
outcomes and recommendation for further work-up or
follow-up. All three forms are completed during the
woman’s first NHMN mammography visit. Patient in-
take and clinical assessment forms are also completed
at subsequent mammography visits, and the question-
naire is updated as possible.
Breast density, the outcome variable, estimates the
proportion of fibroglandular tissue in the breast, rela-
tive to fat. Breast density was recorded on the stan-
dardized clinical assessment form by interpreting
radiologists using the American College of Radiology
Breast Imaging Reporting and Data System
(BI-RADS) classification (1 = fatty, 2 = scattered
density, 3 = heterogeneously dense, and 4 = extremely
dense) [23]. In the event of discordance in the density
of the right and left breast, the woman was classified
according to the higher density classification. Breast
density readings were available for 162,933 (95.4%) of
the 170,815 women who had at least one mammogram
recorded in the registry.
To optimize temporal correspondence between the
women’s characteristics and the classification of
breast density, the statistical analyses were, when
possible, based on the woman’s breast density on the
date of the first recorded mammogram. When data
for variables (other than HT use) were unavailable
for the date of the mammogram, we searched for-
ward in the NHMN records to retrieve replacement
information corresponding to a subsequent mam-
mography visit. Informative forward searches re-
trieved information from subsequent mammographic
encounters occurring, on average, within 24 months
of the index mammogram, and reduced missing val-
ues by 3–9%.
Current body mass index (BMI; kg/m2) was missing
for 18,195 women, and the analyses were confined to
144,018 women for whom this measure was available.
Included in the analytic sample were 131,480 (91%)
women with a screening mammogram, 10,885 (8%)
with a diagnostic mammogram, and 1,653 (1%) for
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whom the reason for the mammogram was not re-
corded. The majority of women, 136,283 (95%) had no
personal history of breast cancer, 6,033 (4%) had a
prior history of breast cancer based on NHMN records
or the patient intake form, and 1,702 (1%) had un-
known breast cancer status.
We used unconditional logistic regression analyses
to generate odds ratios (OR) and 95% confidence
intervals (CI) [24] for the association between factors
and breast density, dichotomized as heterogeneously/
extremely dense (dense) or fatty/scattered density (not
dense). Statistical significance required a probability
value of <0.05 (two-sided test). OR were computed
using the cutpoints shown in the tables. Tests of trend
and the corresponding OR were based on the cate-
gorical (age at menarche) or the continuous form of
the variable (age, BMI, age at first birth, parity), in
accordance with the method of data collection.
Because breast density was inversely associated with
age (p for trend <0.0001) and current BMI (p for trend
<0.0001), terms for these variables, using the continu-
ous form, were included in all models. We found no
evidence of confounding by the other variables shown
in Table 1 (fully adjusted OR were within 10% of
those adjusted for age and BMI). Model building
began with terms representing the main effects, and
included interaction terms involving age, BMI, and
menopausal status as suggested by visual inspection of
the stratified analyses. The presence of statistical
interactions was formally tested using likelihood ratio
tests. The interaction term representing BMI was de-
fined as BMI ‡30 (high BMI), versus <30 (low BMI).
The final multivariable model, based on all women,
contained terms for age and BMI in their continuous
form, BMI (high, low), family history of breast cancer,
age at menarche, age at first birth, parity, menopausal
status, current use of HT, and terms for the interac-
tions involving BMI (high, low) and age at menarche,
age at first birth, and parity, a term for the interaction
involving age and current HT use, and a term for the
interaction between age at first birth and menopausal
status. We repeated the analyses in parous women, in
Table 1 Distribution of women’s characteristics by breast
density, dichotomized as dense versus not dense
Characteristics of study
sample (n = 144,018)
Not dense Dense
n % n %
Age (years)
30–39 6,728 8 10,011 16
40–49 24,970 31 29,954 48
50–59 21,537 27 13,597 22
60–69 15,160 19 5,433 9
70–79 10,349 13 3,039 5
80–89 2,476 3 774 1
All women 81,220 56 62,798 44
Education
<High school 6,887 8 2,703 4
High school graduate 27,485 34 17,291 28
College graduate 35,270 43 31,113 50
Post graduate 9,971 12 10,681 17
Missing 1,607 2 1,010 2
Marital status
Not married 25,235 31 16,905 27
Married 54,181 67 44,598 71
Missing 1,804 2 1,295 2
Current BMI
<20 2,640 3 6,479 10
20–22.49 9,848 12 16,570 26
22.5–24.99 15,480 19 16,060 26
25–27.49 14,266 18 9,812 16
27.5–29.99 12,689 16 6,353 10
30–34.99 15,197 19 5,326 8
35+ 11,100 14 2,198 4
Table 1 continued
Characteristics of study
sample (n = 144,018)
Not dense Dense
n % n %
Family history breast cancer
No 55,591 68 41,234 66
Yes 25,629 32 21,564 34
Age at menarche
<11 6,130 8 3,094 5
11 14,028 17 9,328 15
12 20,928 26 15,833 25
13 22,024 27 18,281 29
14 9,430 12 8,534 14
15+ 7,413 9 6,830 11
Missing 1,267 2 898 1
Age at first birtha
<20 15,537 21 8,554 15
20–24 30,574 41 18,674 34
25–29 16,694 22 14,276 26
30–34 6,038 8 6,705 12
35+ 1,972 3 2,478 4
Missing 4,526 6 5,026 9
Parity
0 5,879 8 7,085 11
1 7,023 9 7,665 12
2 19,791 24 18,262 29
3 17,652 22 13,032 21
4 11,723 14 6,905 11
5+ 13,795 17 5,896 9
Missing 5,357 7 3,953 6
Menopausal status
Premenopausal 29,132 36 37,554 60
Postmenopausal 46,874 58 21,895 35
Missing 5,214 6 3,349 5
HT useb
No 32,829 63 12,867 51
Yes 16,338 31 10,722 42
Missing 2,921 6 1,655 7
a Age at first birth in parous women
b A small proportion of women (5.5%) who reported whether
they used HT did not give their menopausal status
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women with a screening mammogram, and in women
who did not have a personal history of breast cancer.
Results
In all women, scattered density (45%) was most fre-
quently recorded, followed by heterogeneous density
(34%), fatty breasts (12%), and extremely dense
breasts (10%). The distribution of factors by breast
density, classified as not dense versus dense, is shown
in Table 1. In general, based on the cutpoints shown,
there was a tendency for younger women, those with
higher education, and married women to have denser
breasts. Women with lower BMI also had greater
breast density, consistent with our use of BI-RADS
categories, which assess the proportion of fibroglan-
dular tissue (versus fat) in the breast. Women with a
family history of breast cancer, later menarcheal age,
later age at first birth, and low parity had a tendency
toward higher breast density. High breast density was
more common in premenopausal than in postmeno-
pausal women, and in women currently using HT
compared to nonusers.
Age-stratified analyses, adjusted for age and BMI,
showed a weak, positive influence of family history of
breast cancer across all age groups assessed (Table 2).
A small positive association between age at menarche
and breast density appeared to vary by age, with
weaker effects in the older and youngest age groups.
There were no clear age-related patterns for either the
positive effect of age at first birth or the inverse effect
of parity or menopausal status. Current HT use, com-
pared to nonuse, was inversely associated with breast
density in the younger age groups, and positively
associated in women of age 50 or more. In women of
age 70 or more, those using HT, compared to nonusers,
had twice the odds of having dense breasts.
Analyses stratified on BMI suggested that the
influence of some factors was less evident in women of
BMI ‡30 (high BMI) than in those of BMI <30 (low
BMI) (Table 3). In particular, the positive influence of
age at menarche and age at first birth, and the inverse
influence of parity were least apparent in the highest
BMI group. The data suggested an inverse effect of
being postmenopausal, relative to premenopausal,
which decreased consistently across the BMI group-
ings, but the change in OR from the lowest to the
highest BMI group was slight. Although the influence
of current HT use fluctuated somewhat over BMI
groups, there were no obvious patterns.
Analyses stratified by menopausal status revealed
largely similar results for most variables, but the
relationship between age at first birth and breast den-
sity was stronger in the postmenopausal women
(Table 4).
We assessed risk factors and potential interactions in
a multivariable model (Table 5). Only one factor,
family history of breast cancer, which showed a weak
but significant positive effect (OR 1.09; 95% CI 1.05–
1.14) on breast density, was not involved in an inter-
action. The possible interaction involving age and age
at menarche, suggested by the age-stratified analyses,
was not statistically significant (p = 0.10). A statisti-
cally significant interaction was found between current
HT use and age (p < 0.0001). Interactions were also
present between BMI and age at menarche (p = 0.04),
age at first birth (p < 0.0001), and parity (p = 0.01). We
also noted a significant interaction between meno-
pausal status and age at first birth (p = 0.004), but the
coefficients were inconsistent across categories of age
at first birth. When the interaction between meno-
pausal status and age at first birth was omitted from the
multivariable model, results for the remaining terms
were essentially unchanged. A possible interaction
involving age, menopausal status, and HT was not
significant (p = 0.10).
We repeated the analyses in the subgroup of women
who did not have a personal history of breast cancer,
and found similar results (Table 5). The findings were
also comparable when the analyses were confined to
parous women, or to those with a screening mammo-
gram (data not shown).
Discussion
Evidence accumulating for nearly 30 years supports
the association between breast density and breast
cancer [1–5]. Although the notion remains controver-
sial, breast density may be a biomarker of risk [25]. In
addition to its influence on breast cancer risk, breast
density reduces the accuracy of screening mammogra-
phy [11, 12, 26, 27], particularly in younger women [9]
who tend to have denser breasts [28]. Perhaps as a
direct consequence of reduced screening accuracy,
breast density is associated with increased risk of
interval breast cancers [11], with an adverse impact on
breast cancer prognosis.
Most studies of breast cancer risk have shown an
inverse effect of age at menarche [13–15, 29], but
previous studies of the relationship between age at
menarche and breast density have produced inconsis-
tent results. A positive association was seen in two
studies [16, 18], including a large HMO population of
nearly 30,000 women in Seattle [16]. Studies of breast
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cancer family members [17], Singaporean women [20],
and Hispanic women [19] found no association
between menarcheal age and breast density. Findings
from the HMO-based study suggested the positive ef-
fect of age at menarche was stronger in the youngest
and oldest age groups [16], whereas a study of nearly
5,000 women in Guernsey found significant positive
effects only in postmenopausal women [6]. In contrast,
our age-stratified analyses suggested weaker effects in
the oldest age groups, although the interaction
involving age and age at menarche was not statistically
significant. Also in this study, analyses stratified on
BMI suggested that age at menarche was positively
associated with breast density in most BMI groups, but
the association was tenuous in women with high BMI,
and the interaction involving age at menarche and high
BMI was statistically significant. A positive association
between age at menarche and breast density, even if
confined to women with lower BMI, seems paradoxi-
cal, given the usual inverse association between age
at menarche and breast cancer and the strong
positive association between breast density and breast
cancer risk.
Consistent with some [16–18, 20, 30, 31], but not all
[6, 19] previous efforts, our findings show that age at
first birth and parity are generally associated with
Table 2 Odds ratios (OR) and 95% confidence intervals (CI) for the association with breast density according to age group
Characteristica Age group
<40 40–49 50–59 60–69 70+
n = 16,739 n = 54,924 n = 35,134 n = 20,593 n = 16,628
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Family history breast cancer
No Reference Reference Reference Reference Reference
Yes 1.06 (0.99, 1.13) 1.10 (1.06, 1.14) 1.07 (1.02, 1.13) 1.10 (1.03, 1.18) 1.11 (1.02, 1.20)
Age at menarche
Overall OR (95% CI)b 1.04 (1.01, 1.06) 1.06 (1.05, 1.08) 1.03 (1.02, 1.05) 1.01 (0.99, 1.03) 1.01 (0.98, 1.03)
p for trendb 0.002 <0.0001 0.0001 0.31 0.70
<11 Reference Reference Reference Reference Reference
11 0.99 (0.85, 1.18) 1.14 (1.04, 1.24) 1.28 (1.15, 1.42) 1.06 (0.90, 1.24) 1.11 (0.89, 1.38)
12 1.04 (0.89, 1.21) 1.15 (1.06, 1.25) 1.26 (1.15, 1.39) 1.12 (0.96, 1.30) 1.18 (0.96, 1.45)
13 1.15 (0.98, 1.35) 1.25 (1.16, 1.36) 1.27 (1.15, 1.40) 1.20 (1.03, 1.39) 1.00 (0.82, 1.23)
14 1.21 (1.02, 1.44) 1.34 (1.22, 1.46) 1.37 (1.23, 1.53) 1.23 (1.05, 1.46) 1.22 (0.99, 1.51)
15+ 1.29 (1.08, 1.55) 1.45 (1.32, 1.60) 1.36 (1.21, 1.52) 1.05 (0.89, 1.25) 1.15 (0.92, 1.43)
Age at first birthc
Overall OR (95% CI)d 1.08 (1.06, 1.10) 1.05 (1.04, 1.06) 1.07 (1.06, 1.08) 1.07 (1.05, 1.09) 1.06 (1.05, 1.08)
p for trendd <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
<20 Reference Reference Reference Reference Reference
20–24 1.06 (0.95, 1.19) 1.14 (1.08, 1.21) 1.21 (1.14, 1.29) 1.23 (1.12, 1.34) 1.07 (0.93, 1.24)
25–29 1.09 (0.98, 1.22) 1.19 (1.12, 1.26) 1.40 (1.30, 1.51) 1.51 (1.36, 1.68) 1.28 (1.11, 1.49)
30–34 1.35 (1.18, 1.53) 1.23 (1.15, 1.36) 1.58 (1.42, 1.76) 1.64 (1.39, 1.95) 1.42 (1.18, 1.70)
35+ 1.67 (1.30, 2.16) 1.48 (1.35, 1.63) 1.85 (1.58, 2.17) 1.90 (1.44, 2.49) 1.47 (1.14, 1.91)
Parity
Overall OR (95% CI)d 0.86 (0.84, 0.88) 0.91 (0.90, 0.93) 0.90 (0.86, 0.91) 0.89 (0.87, 0.90) 0.87 (0.85, 0.89)
p for trendd <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
0 Reference Reference Reference Reference Reference
1 0.74 (0.65, 0.86) 0.90 (0.83, 0.87) 0.87 (0.79, 0.97) 0.87 (0.73, 1.05) 0.88 (0.73, 1.05)
2 0.58 (0.52, 0.66) 0.73 (0.69, 0.78) 0.77 (0.71, 0.85) 0.77 (0.67, 0.89) 0.66 (0.57, 0.78)
3 0.48 (0.42, 0.55) 0.69 (0.65, 0.74) 0.67 (0.61, 0.73) 0.65 (0.57, 0.76) 0.59 (0.51, 0.69)
4 0.49 (0.42, 0.57) 0.61 (0.57, 0.66) 0.61 (0.55, 0.67) 0.55 (0.48, 0.64) 0.49 (0.42, 0.58)
5+ 0.38 (0.33, 0.45) 0.60 (0.55, 0.66) 0.52 (0.47, 0.58) 0.49 (0.42, 0.56) 0.39 (0.33, 0.46)
Menopausal status
Premenopausal Reference Reference Reference
Postmenopausal 0.69 (0.60 , 0.79 ) 0.71 ( 0.68, 0.75) 0.71 (0.67, 0.75) N/A N/A
HT use
No Reference Reference Reference Reference Reference
Yes 0.69 (0.57, 0.84) 0.80 (0.75, 0.86) 1.39 (1.32, 1.46) 1.82 (1.70, 1.95) 2.02 (1.84, 2.22)
a Adjusted for age and current BMI as continuous variables
b Based on the cutpoints shown
c Among parous women
d Based on the continuous form of the variable
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breast density in a pattern resembling known associa-
tions with breast cancer risk. However, our stratified
analyses indicate that the influence of the reproductive
variables is less pronounced in women with high BMI,
and our modeling results confirmed interactions
involving BMI and both variables. These findings,
along with our findings for age at menarche, are con-
sistent with the possibility that hormonal or repro-
ductive events are less influential in heavier women,
whose circulating hormone levels may be influenced by
conversion in peripheral adipose tissue. We also noted
a stronger positive influence of age at first birth in
postmenopausal women, although a previous study of
Native American women found stronger effects in
premenopausal women [30]. Our sample was large, and
the multivariable results were inconsistent across cat-
egories of age at first birth; thus, it is possible the
interaction between menopausal status and age at first
birth was due to statistical artifact rather than true
effect modification.
Only one variable, family history of breast cancer,
was not involved in interactions with age, BMI, or
menopausal status. Although previous studies have not
shown an effect of family history on breast density [3,
6, 19], this is likely due to limited power to detect a
weak association. The modest inverse effect of meno-
pausal status has been noted previously [19, 20, 30].
Most previous reports, although not all [20], found a
Table 3 Odds ratios (OR) and 95% confidence intervals (CI) for the association with breast density according to BMI group
Characteristica Current BMI
<22.5 22.5–25.49 25.5–27.49 27.5–29.99 ‡30
n = 35,547 n = 37,153 n = 18,744 n = 18,775 n = 33,799
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Family history of breast cancer
No Reference Reference Reference Reference Reference
Yes 1.09 (1.03, 1.14) 1.03 (0.99, 1.08) 1.08 (1.01, 1.15) 1.15 (1.08, 1.23) 1.09 (1.03, 1.15)
Age at menarche
Overall OR (95% CI)b 1.04 (1.03, 1.06) 1.05 (1.03, 1.06) 1.04 (1.02, 1.06) 1.03 (1.01, 1.05) 1.01 (0.99, 1.03)
p for trendb <0.001 0.001 0.001 0.004 0.25
<11 Reference Reference Reference Reference Reference
11 1.25 (1.09, 1.43) 1.17 (1.05, 1.31) 1.13 (0.98, 1.31) 1.20 (1.05, 1.38) 1.10 (0.99, 1.22)
12 1.36 (1.20, 1.55) 1.26 (1.13, 1.40) 1.10 (0.96, 1.27) 1.16 (1.01, 1.32) 1.09 (0.98, 1.21)
13 1.43 (1.26, 1.63) 1.33 (1.20, 1.48) 1.16 (1.01, 1.33) 1.21 (1.06, 1.38) 1.06 (0.94, 1.16)
14 1.54 (1.34, 1.75) 1.44 (1.28, 1.61) 1.25 (1.08, 1.45) 1.19 (1.02, 1.38) 1.16 (1.02, 1.31)
15+ 1.52 (1.32, 1.75) 1.43 (1.27, 1.61) 1.26 (1.07, 1.48) 1.33 (1.13, 1.56) 1.06 (0.93, 1.21)
Age at first birthc
Overall OR (95% CI)d 1.08 (1.07, 1.09) 1.07 (1.06, 1.08) 1.07 (1.06, 1.09) 1.06 (1.04, 1.07) 1.03 (1.02, 1.04)
p for trendd <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
<20 Reference Reference Reference Reference Reference
20–24 1.21 (1.13, 1.31) 1.20 (1.13, 1.28) 1.15 (1.05, 1.26) 1.13 (1.03, 1.23) 1.04 (0.96, 1.11)
25–29 1.39 (1.29, 1.51) 1.34 (1.25, 1.44) 1.21 (1.10, 1.34) 1.31 (1.19, 1.45) 1.10 (1.01, 1.19)
30–34 1.45 (1.32, 1.60) 1.55 (1.42, 1.70) 1.40 (1.23, 1.59) 1.42 (1.25, 1.63) 1.11 (0.99, 1.24)
35+ 1.79 (1.56, 2.06) 1.84 (1.61, 2.09) 1.88 (1.56, 2.28) 1.62 (1.33, 1.97) 1.29 (1.08, 1.53)
Parity
Overall OR (95% CI)d 0.86 (0.85, 0.87) 0.88 (0.87, 0.89) 0.90 (0.88, 0.92) 0.91 (0.89, 0.93) 0.93 (0.92, 0.95)
p for trendd <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
0 Reference Reference Reference Reference Reference
1 0.75 (0.67, 0.84) 0.80 (0.73, 0.89) 0.93 (0.81, 1.08) 1.13 (0.98, 1.30) 0.95 (0.85, 1.07)
2 0.61 (0.55, 0.66) 0.67 (0.62, 0.73) 0.74 (0.66, 0.84) 0.90 (0.79, 1.02) 0.85 (0.78, 0.94)
3 0.52 (0.48, 0.58) 0.58 (0.53, 0.63) 0.68 (0.60, 0.77) 0.80 (0.71, 0.91) 0.81 (0.73, 0.89)
4 0.44 (0.39, 0.48) 0.52 (0.47, 0.57) 0.60 (0.52, 0.69) 0.71 (0.62, 0.81) 0.75 (0.68, 0.84)
5+ 0.37 (0.34, 0.41) 0.44 (0.40, 0.48) 0.52 (0.45, 0.60) 0.64 (0.56, 0.74) 0.66 (0.59, 0.74)
Menopausal status
Premenopausal Reference Reference Reference Reference Reference
Postmenopausal 0.67 (0.63, 0.72) 0.68 (0.64, 0.72) 0.71 (0.65, 0.77) 0.73 (0.67, 0.79) 0.75 (0.70, 0.80)
HT use
No Reference Reference Reference Reference Reference
Yes 1.23 (1.15, 1.31) 1.33 (1.26, 1.42) 1.34 (1.23, 1.46) 1.41 (1.30, 1.55) 1.34 (1.25, 1.45)
a Adjusted for age and current BMI as continuous variables
b Based on the cutpoints shown
c Among parous women
d Based on the continuous form of the variable
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positive association between use of HT and breast
density [16, 17, 19, 30, 32, 33], resembling the
well-known association between use of these hormones
and breast cancer risk. The large size of our study al-
lowed an assessment of HT use in young postmeno-
pausal women, and these analyses showed a modest
but significant inverse effect in postmenopausal women
less than 50 years of age, a phenomenon that has no
clear explanation. In women of age 50 or more, the
positive effect of HT on density increased with age,
perhaps reflecting a corresponding decrease in density
in untreated women in the same age group. Consistent
with our findings, at least two previous studies of breast
density showed an increasing effect of HT use when
examined over increasing age groups [16, 32]. A pro-
spective study of breast cancer risk also noted stronger
HT effects in older women [37], although this is not
always seen [36]. The age-related increase observed in
our study could potentially reflect a longer duration of
HT use, but at least two studies have shown that most
of the increase in breast density occurs soon after HT
initiation [33, 34], and duration of use was not associ-
ated with increased breast density in the HMO study
[16]. In contrast, the positive influence of HT on breast
cancer risk is usually observed for current/recent and
long-term use [35–40]. While speculative, it is possible
that sustained breast density associated with long term
HT use mediates the relationship between HT and
breast cancer risk. Finally, our data did not indicate a
stronger effect of HT on breast density in leaner wo-
man, but a few studies [38–40], including a collabora-
tive analysis of 51 studies [38], suggested a stronger
association between HT and breast cancer risk in
leaner women.
Although the type of HT used (estrogen alone or
estrogen combined with progesterone) was not as-
sessed in our study, a possible role of progesterone is
suggested by reports that breast density is greater
during the luteal phase of the menstrual cycle [41–43].
In addition, at least two studies have found substan-
Table 4 Odds ratios (OR)
and 95% confidence intervals
(CI) for the association with
breast density according to
menopausal status
a Adjusted for age and
current BMI as continuous
variables
b Among parous women
c Based on the continuous
form of the variable
Characteristica Menopausal status
Premenopausal Postmenopausal
n = 66,686 n = 68,769
OR (95% CI) OR (95% CI)
Family history of breast cancer
No Reference Reference
Yes 1.09 (1.05, 1.13) 1.08 (1.04, 1.12)
Age at first birth
Overall OR (95% CI) 1.05 (1.04, 1.06) 1.03 (1.02, 1.04)
p for trend <0.0001 <0.0001
<11 Reference Reference
11 1.12 (1.03, 1.21) 1.15 (1.06, 1.25)
12 1.12 (1.04, 1.22) 1.20 (1.12, 1.30)
13 1.22 (1.13, 1.32) 1.21 (1.12, 1.31)
14 1.31 (1.21, 1.43) 1.29 (1.18, 1.40)
‡15 1.40 (1.28, 1.53) 1.25 (1.15, 1.36)
Age at first birthb
Overall OR (95% CI)c 1.05 (1.05, 1.06) 1.07 (1.06, 1.08)
p for trendc <0.0001 <0.0001
<20 Reference Reference
20–24 1.07 (1.01, 1.13) 1.21 (1.15, 1.27)
25–29 1.11 (1.05, 1.17) 1.41 (1.33, 1.49)
30–34 1.21 (1.13, 1.29) 1.57 (1.45, 1.71)
‡35 1.48 (1.35, 1.62) 1.77 (1.57, 2.00)
Parity
Overall OR (95% CI)c 0.90 (0.87, 0.91) 0.88 (0.88, 0.89)
p for trendc <0.0001 <0.0001
0 Reference Reference
1 0.87 (0.81, 0.93) 0.86 (0.79, 0.93)
2 0.70 (0.66, 0.74) 0.72 (0.68, 0.77)
3 0.63 (0.60, 0.68) 0.62 (0.58, 0.67)
4 0.57 (0.53, 0.62) 0.55 (0.51, 0.59)
‡5 0.52 (0.49, 0.57) 0.46 (0.43, 0.50)
HT use
No NA Reference
Yes NA 1.47 (1.41, 1.52)
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tially greater changes in parenchymal patterns in
women initiating use of a combined estrogen plus
progesterone hormone regimen, as opposed to single
agent estrogen [33, 34]. Results from the Women’s
Health Initiative randomized clinical trials of post-
menopausal hormones also indicate that the increased
risk of breast cancer is due to the combined regimen
[44] rather than single agent estrogen [45].
Strengths of our study include the large size of our
sample, allowing analyses stratified by relatively
refined age and BMI groups, which has not been pos-
sible in most previous studies, and good representation
of the underlying population. Epidemiologic data were
obtained on the time of the mammographic visit,
ensuring updated information, and importantly, a high
level of correspondence between use of hormone
Table 5 Betas (b) and
standard errors (SE) for the
association between factors
and breast density in all
women and in subgroupsa
a Based on a multivariable
model containing all terms
shown in the table
b The nulliparous parameter
and its interaction with BMI
were set to 0, since these
variables were linear
combinations of other
variables
Characteristic All women n = 144,018
b (SE)
Women without breast
cancer n = 136,283
b (SE)
Intercept 4.82 (0.17) 4.88 (0.17)
Age –0.04 (0.001) –0.04 (0.001)
Current BMI –0.12 (0.003) –0.12 (0.003)
Family history of breast cancer 0.09 (0.02) 0.09 (0.02)
BMI <30 –0.53 (0.11) –0.53 (0.11)
Postmenopausal –0.43 (0.09) –0.43 (0.09)
HT use –1.22 (0.11) –1.25 (0.11)
Age at menarche
15+ –0.01 (0.10) –0.03 (0.11)
14 0.04 (0.10) 0.01 (0.10)
13 –0.01 (0.08) –0.03 (0.08)
12 0.08 (0.08) 0.06 (0.08)
11 0.04 (0.08) 0.02 (0.08)
BMI <30 * Age at menarche
15+ 0.30 (0.12) 0.32 (0.12)
14 0.24 (0.11) 0.28 (0.11)
13 0.22 (0.09) 0.24 (0.10)
12 0.12 (0.09) 0.15 (0.10)
11 0.11 (0.10) 0.14 (0.10)
Age at first birth
Nulliparous 0.38 (0.16) 0.13 (0.17)
35+ 0.19 (0.22) 0.25 (0.23)
30–34 –0.19 (0.15) –0.18 (0.15)
25–29 –0.11 (0.12) –0.12 (0.12)
20–24 0.14 (0.11) 0.13 (0.11)
BMI <30 * Age at first birth
Nulliparous 0.57 (0.10) 0.59 (0.11)
35+ 0.41 (0.18) 0.40 (0.18)
30–34 0.31 (0.11) 0.32 (0.12)
25–29 0.12 (0.08) 0.15 (0.08)
20–24 0.06 (0.06) 0.06 (0.06)
Postmenopausal * Age at first birth
Nulliparous 0.09 (0.15) 0.10 (0.15)
35+ –0.08 (0.19) –0.14 (0.19)
30–34 0.27 (0.13) 0.26 (0.13)
25–29 0.25 (0.11) 0.23 (0.11)
20–24 –0.05 (0.10) –0.04 (0.11)
Paritya
1 0.29 (0.09) 0.28 (0.09)
2 0.22 (0.07) 0.23 (0.07)
3 0.14 (0.07) 0.17 (0.07)
4 0.09 (0.07) 0.11 (0.08)
BMI <30 * Parityb
1 0.30 (0.10) 0.30 (0.10)
2 0.22 (0.07) 0.20 (0.08)
3 0.18 (0.08) 0.15 (0.08)
4 0.09 (0.08) 0.07 (0.09)
Age * HT use 0.03 (0.002) 0.03 (0.002)
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replacement therapy and the assessment of breast
density. Limitations of our study include 11% of
women for whom BMI is missing, reliance of self-re-
port for BMI, and a lack of information regarding the
type and duration of HT use. Our definition of family
history of breast cancer included second degree rela-
tives, which may have attenuated the effect of this
variable. Also, the BI-RADS scores are qualitative, as
opposed to digital quantification of density, and were
applied by community radiologists, who despite being
trained to use this system, may apply it differently.
Nevertheless, our general findings in terms of the
direction of effects for reproductive factors and HT use
were compatible with those of most previous studies.
In conclusion, our results, based on the largest
study to date, confirm earlier findings that most
established breast cancer risk factors behave similarly
in relation to breast density, consistent with the no-
tion that breast density mediates breast cancer risk.
However, our data indicated an inverse effect of HT
in younger women, and a positive influence in older
women, which has not been reported previously. We
also noted effect modification by BMI, in which the
positive effects of age at menarche and age at first
birth, and the inverse effects of parity were less
apparent in heavier women. Further investigation,
including biological studies, may elucidate the com-
plex interrelationships of hormones, BMI, breast
density, and breast cancer and potentially offer
opportunities for breast cancer prevention.
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